Liu Baolong, Nguyen Phuong Linh, Yu Han, Li Xingzhi, Wang Huiren, Nguyen Tram Gia Bao, Sahoo Prakash Kumar, Sur Meghna, Reddy Jay, Sillman Sarah, Kachman Stephen D, Altartouri Bara, Lu Guoqing, Natarajan Sathish Kumar, Pattabiraman Mahesh, Yu Jiujiu
Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
Shaanxi Key Laboratory of Molecular Biology for Agriculture, College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China.
Acta Pharm Sin B. 2024 Aug;14(8):3661-3679. doi: 10.1016/j.apsb.2024.05.002. Epub 2024 May 10.
Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), has emerged as the leading cause of liver failure and related death. Currently, no medication is specifically approved to treat NAFLD or NASH. Here we report that oral administration of honey vesicle-like nanoparticles (H-VLNs) to naturally aged mice protects the liver from NASH development. H-VLNs are dominantly taken up by Kupffer cells in the liver and suppress hepatic chronic inflammation and further development of fibrosis and nodule formation in aged mice. Besides their reported anti-inflammasome function, H-VLNs are found to inhibit the transcriptional activities of C-JUN and nuclear factor-kappa B (NF-B). MicroRNAs miR5119 and miR5108 and phenolic compound luteolin in H-VLNs are identified in suppressing both the C-JUN and NF-B pathways. Collectively, oral intake of H-VLNs represents a promising new user-friendly modality to prevent the development of NASH.
非酒精性脂肪性肝炎（NASH）是非酒精性脂肪肝病（NAFLD）的一种晚期形式，已成为肝衰竭及相关死亡的主要原因。目前，尚无专门获批用于治疗NAFLD或NASH的药物。在此，我们报告称，给自然衰老的小鼠口服蜂蜜囊泡样纳米颗粒（H-VLNs）可保护肝脏免受NASH发展的影响。H-VLNs主要被肝脏中的库普弗细胞摄取，并抑制老年小鼠肝脏的慢性炎症以及纤维化和结节形成的进一步发展。除了其已报道的抗炎症小体功能外，还发现H-VLNs可抑制C-JUN和核因子-κB（NF-κB）的转录活性。已确定H-VLNs中的微小RNA miR5119和miR5108以及酚类化合物木犀草素可抑制C-JUN和NF-κB途径。总体而言，口服H-VLNs是一种有前景的、新的、用户友好型预防NASH发展的方式。
